WHAT IS CLAIMED:

1. An isolated stimulated placental derived adherent cell, wherein said cell is adherent to tissue culture plastic, and wherein said cell is CD10+, $CD34^-$, $CD105^+$ and $CD200^+$, wherein said cell has been contacted with one or more pro-inflammatory cytokines in vitro, and wherein said cell (1) promotes the proliferation of endothelial cells; (2) promotes the formation of sprouts or tube-like structures in a population of endothelial cells; or (3) promote the migration of endothelial cells.

2. The isolated cell of claim 1, wherein said cell is CD10+, $CD34^-$, $CD105^+$ and $CD200^+$ as determined by flow cytometry.

3. The isolated cell of claim 1, wherein said pro-inflammatory cytokine is one or more of IL-1 α, IL-1 β, IL-6, IL-8, IL-18, TNF-α, or INF-γ.

4. The isolated cell of claim 3, wherein said pro-inflammatory cytokine is IL-1 β.

5. The isolated cell of any of claims 1-4, wherein said cell secretes trophic factors at a higher level than an isolated placental derived adherent cell that has not been contacted with said one or more pro-inflammatory cytokines.

6. The isolated cell of claim 5, wherein said trophic factors comprise at least one of GM-CSF, G-CSF, IL-6, GRO, MCP-1, Follistatin, or IL-8.

7. The isolated cell of claim 5, wherein said trophic factors comprise GM-CSF, G- CSF, IL-6, GRO, MCP-1, Follistatin, and IL-8.

8. An isolated population of cells comprising the cell of any of claims 1-7.

9. The isolated population of cells of claim 8, wherein at least 50% of the cells in said population are the cells of claim 1.

10. The isolated population of cells of claim 8, wherein at least 90% of the cells in said population are the cells of claim 1.

11. Use of a population of the cells of any one of claims 1-7 in the manufacture of a medicament for treating an individual having a disease or disorder of the circulatory system, the population of the cells is to be administered to said individual.

12. The use of claim 11, wherein the population of the cells of claim 1 is to be administered to said individual in an amount and for a time sufficient for detectable improvement of one or more symptoms of said disease or disorder.

13. The use of claim 11 or 12, wherein said disease or disorder is diabetic foot ulcer (DFU).

14. The use of claim 13, wherein said DFU is caused by and/or associated with peripheral arterial disease (PAD).

15. The use of claim 11, wherein said disease or disorder of the circulatory system is a heart disease or injury.

16. The use of claim 11, wherein said disease or disorder is a disruption of blood flow in or around a limb.

17. The use of claim 16, wherein said disruption of blood flow in or around a limb is caused by a peripheral arterial disease (PAD) or a peripheral vascular disease (PVD).

18. The use of claims 11 to 13, wherein said disease or disorder is peripheral arterial disease (PAD).

19. The use of claims 11 to 13, wherein said disease or disorder is peripheral vascular disease (PVD).

20. The use of claims 11 to 19, wherein the population of cells of claim 1 is to be administered to said individual intramusculatory on day 1 and day 8 at concentrations of (i) 3×10^6; (ii): 1×10^7; or (iii) 3×10^7 of said cells.

21. The use of claims 11 to 19, wherein the population of cells of claim 1 is to be administered to said individual intramusculatory on days 1, 29, and 57 at concentrations of 3×10^6; or 3×10^7 of said cells.

22. The use of claims 11 to 21, wherein one or more indicia of cardiac function is detectibly improved, wherein said indicia of cardiac function are chest cardiac output (CO), cardiac index (CI), pulmonary artery wedge pressure (PAWP), cardiac index (CI), % fractional shortening (%FS), ejection fraction (EF), left ventricular ejection fraction (LVEF); left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), contractility (dP/dt), a decrease in atrial or ventricular functioning, an increase in pumping efficiency, a decrease in the rate of loss of pumping efficiency, a decrease in loss of hemodynamic functioning, or decrease in complications associated with cardiomyopathy, as compared to the individual prior to administration of placental derived adherent cells.

23. Use of a population of the cells of any one of claims 1-8 in the manufacture of a medicament for treating an individual having a disease or disorder of the circulatory system, the population of the cells is to be administered to said individual, wherein one or more indicia of cardiac function is detectibly improved, wherein said indicia of cardiac function are chest cardiac output (CO), cardiac index (CI), pulmonary artery wedge pressure (PAWP), cardiac index (CI), % fractional shortening (%FS), ejection fraction (EF), left ventricular ejection fraction (LVEF); left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), contractility (dP/dt), a decrease in atrial or ventricular functioning, an increase in pumping efficiency, a decrease in the rate of loss of pumping efficiency, a decrease in loss of hemodynamic functioning, or decrease in complications associated with cardiomyopathy, as compared to the individual prior to administration of placental derived adherent cells.

24. The use of claim 23, wherein the population of the cells of any one of claims 1-8 is to be administered to said individual in an amount and for a time sufficient for detectable improvement of one or more said indicia of cardiac function.

25. The use of claims 23 or 24, wherein said disease or disorder of the circulatory system is a heart disease or injury.

26. Use of a population of the cells of any one of claims 1-8 in the manufacture of a medicament for treating an individual having a disruption of blood flow in or around a limb, the population of the cells is to be administered to the individual.

27. The use of claim 26, wherein said disruption of blood flow in or around the limb is a peripheral arterial disease (PAD) or a peripheral vascular disease (PVD).

28. The use of any one of claims 11 to 27, wherein the the population of the cells is to be administered to the individual with a further therapeutic agent.

29. The use of any one of claims 11 to 28, wherein the population of the cells is to be administered to the individual by transplantation, implantation, injection, infusion, or delivery via catheter.

30. A method of producing a stimulated placental derived adherent cell, wherein said cell is $CD10^+$, $CD34^-$, $CD105^+$ and $CD200^+$, the method comprising contacting a placental derived adherent cell with one or more pro-inflammatory cytokines in vitro.

31. The method of claim 30, wherein the pro-inflammatory cytokine is one or more of IL-1 α, IL-1 β, IL-6, IL-8, IL-18, TNF-α, or INF-γ.

32. The method of claim 30 or 31, wherein the pro-inflammatory cytokine is IL-Iβ.

33. A pharmaceutical composition comprising a population of the cells of any one of claims 1-8 and a pharmaceutically-acceptable carrier.

34. A kit of parts comprising a population of the cells of any one of claims 1-8